Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer

Publication Date: April 4, 2023

Key Points

Key Points

  • This guideline focuses on patients with advanced, recurrent, or metastatic prostate cancer and noncastrate testosterone levels whose disease is not yet castration-resistant, including those with biochemical recurrence only.
  • The future of noncastrate advanced, recurrent, or metastatic prostate cancer care is predicted to include highly personalized treatment plans based on advanced genetic testing, next generation imaging, and the availability of highly predictive biomarkers.
  • This targeted update is driven by results from recent Phase III clinical trials (ARASENS, PEACE-1, ENZAMET, and ARCHES) and two recent meta-analyses.

Treatment

...reatmen...

...nitial Treatmen...

...tion 1.0(Updated) Docetaxel, abiraterone, enzalut...

...PRIVATION THERAPY (ADT) PLUS DOCETAXEL...

Recommendation 1.1(Updated) For patients...

...mendation 1.11(New) For patients with de novo...

...1.15(New) For patients with de novo me...

...on 1.16(New) The recommended regimen for...

...1.2(Updated) For patients with low-volume...

...commendation 1.3(Updated) For patients wit...

...T PLUS ABIRATERON...

...dation 1.4For patients with high-risk de novo me...

...ecommendation 1.5For patients with low-ri...

...ation 1.6The recommended regimen fo...

...US ENZALUTAMIDE...

...ation 1.7(Updated) ADT plus enzalut...

....8(Updated) The recommended regimen for patients...

...PLUS APALUTAMIDE...

Recommendation 1.9ADT plus apalutamide...

...endation 1.95(Updated) The recommended regimen f...


...nation Therapies...

...ation 2.1ADT plus abiraterone and prednisolone sho...

...2.2In resource-constrained settings where d...


...drogen Deprivation...

...mmendation 3.1Early (immediate) ADT...


...tent Androgen Deprivation...

...ommendation 4.1Intermittent therapy may b...


...Initial Management of Noncastrate Metastat...